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Exercise in women with Polycystic Ovary Syndrome (PCOS) 
This chapter will summarise the current research on using exercise to manage PCOS. 
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Polycystic Ovary Syndrome (PCOS) is a complex endocrinopathy, affecting both the metabolism and 
reproductive system of women of reproductive age. Prevalence ranges from 6.1% to 19.9% depending 
on the criteria used to give a diagnosis. PCOS accounts for approximately 80% of women with 
anovulatory infertility. PCOS causes disruption at various stages of the reproductive axis. Evidence 
suggests lifestyle modification should be the first line of therapy for women with PCOS. Several 
studies have examined the impact of exercise interventions on reproductive function, with results 
indicating improvements in menstrual and/or ovulation frequency following exercise. Enhanced 
insulin sensitivity underpins the mechanisms of how exercise restores reproductive function. Women 
with PCOS typically have a cluster of metabolic abnormalities that are risk factors for CVD. There is 
irrefutable evidence that exercise mitigates CVD risk factors in women with PCOS. The mechanism 
by which exercise improves many CVD risk factors is again associated with improved insulin 
sensitivity and decreased hyperinsulinemia. In addition to cardiometabolic and reproductive 
complications, PCOS has been associated with an increased prevalence of mental health disorders. 
Exercise improves psychological well-being in women with PCOS, dependent on certain 
physiological factors. An optimal dose-response relationship to exercise in PCOS may not be feasible 
because of the highly individualised characteristics of the disorder. Guidelines for PCOS suggest at 
least 150 minutes of physical activity per week. Evidence confirms that this should form the basis of 
any clinician or healthcare professional prescription. 
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1.1 Diagnosis and Prevalence 
Polycystic Ovary Syndrome (PCOS) is a complex endocrinopathy affecting both the metabolism and 
reproductive system in women of reproductive age [1] . Currently, three sets of diagnostic criteria 
exist; 1) the National Institutes of Health (NIH) criteria from 1990, 2) the American Society of 
Reproductive Medicine sponsored European Society of Human Reproduction and Embryology 
(ASRM/ESHRE) criteria revised in 2003, and 3) the Androgen Excess and Polycystic Ovary 
Syndrome (AE-PCOS) Society criteria from 2009 [2]. Each of the criteria is predicated on the 
presentation of the main characteristics of PCOS; polycystic ovaries (PCO), clinical or biochemical 
hyperandrogenism (excessive levels of androgens), and chronic oligo-anovulation (infrequent or 
absent ovulation) [2]. 
The NIH criteria indicates that chronic anovulation and clinical or biochemical hyperandrogenism 
must both be present [3]. The ASRM/ESHRE criteria is known as the Rotterdam criteria, named after 
the place where the consensus meeting was held. The criteria states that of the main characteristics 
(PCO, clinical or biochemical hyperandrogenism, and chronic oligo-anovulation), any two of the three 
could be present [4]. Both of the aforementioned criteria stipulate that other disorders that could be 
responsible for these symptoms must be excluded first, such as congenital adrenal hyperplasia, 
Cushing’s syndrome, which is a condition caused by excessive adrenal production of cortisol, 
androgen secreting tumours and hyperprolactinemia, where an individual has excessive serum levels 
of prolactin [2]. The more recent AE-PCOS criteria is based on three conditions: hyperandrogenism 
(clinical or biochemical), ovarian dysfunction (encompassing both PCO and oligo-anovulation) and 
the exclusion of other androgen excess related disorders [5]. 
The prevalence of PCOS therefore depends on which criteria is used. Reports of prevalence range 
from 6.1% to 19.9% [6]. Table 1 indicates reported prevalence from studies using different diagnostic 
criteria in Australia [7], Turkey [6] and Iran [8].  
Table 1. Prevalence of PCOS (%) based on individual criteria* 
 Diagnostic Criteria 
NIHa AESb Rotterdamc 
March et al. [7] 8.7 12.0 17.8 
Yildiz et al. [6] 6.1 15.3 19.9 
Mehrabian et al. [8] 7.0 7.9 15.2 
* adapted from Burks & Wild [2] 
aNational Institutes of Health international conference 1990 
b Androgen Excess Society diagnostic criteria 2009  
cTask force sponsored by the European Society of Human Reproductive and Embryology (ESHRE) and the American 
Society for Reproductive Medicine (ASRM), 2003 
 
It is clear from the data in table 1 that the Rotterdam criteria is the least restrictive, because the NIH 
and AE-PCOS criteria both consider hyperandrogenism as a central facet in the pathogenesis of PCOS 
indicating  this should be present along with PCO or oligo-anvoluation [9]. The Rotterdam criteria 
allows for additional phenotypes of PCOS, such as those with PCO and menstrual irregularity without 
hyperandrogenism. Nevertheless, it can be considered as an emerging epidemic that needs to be 
attenuated due to numerous debilitating symptoms and co-morbidities.  
 
1.2 Associated Symptoms and Co-morbidities 
Though not acknowledged in the diagnostic criteria, women with PCOS often have higher amounts of 
visceral fat (around the organs in the peritoneal cavity)  [10], up to 80% prevalence of insulin 
resistance [11] and up to 70% prevalence of dyslipidemia [12]. PCOS is associated with reproductive 
and cardiometabolic complications and increased risk of cardiovascular diseases (CVD); forty percent 
of women with PCOS are affected by infertility [13], while there is a two to four-fold higher 
incidence of metabolic syndrome in the PCOS population in comparison to weight-matched healthy 
women [14]. This is primarily true for those phenotypes presenting with hyperandrogenism; this 
phenotype has been associated with a metabolic profile that encompasses higher incidences of insulin 
resistance and a worse lipid profile than those women with a normo-androgenic profile, despite 
comparable distributions of body weight [15]. 
It is hypothesised that insulin resistance underpins this worse metabolic profile rather than androgen 
excess itself. Insulin acts as a co-gonadotropin, stimulating the ovary to produce testosterone, whilst 
simultaneously inhibiting the production of sex hormone binding globulin (SHBG) which leads to a 
higher concentration of bio-available testosterone [16]. Additionally hyperinsulinemia can lead to 
hepatic overproduction of very low density lipoproteins (VLDL), and elevation in triglycerides (TG) 
through decreased lipoprotein lipase-mediated lipolysis, leading to increased circulating chylomicrons 
and VLDL [17]. Skeletal muscle insulin resistance may also promote dyslipidemia by re-directing 
dietary carbohydrate sources away from skeletal muscle glycogen synthesis into hepatic de novo 
lipogenesis, and subsequently increased circulating triglycerides assembled from glucose substrates 
and a reduction in high-density lipoprotein (HDL) concentrations [18]. 
1.3 Treatment 
It is difficult to isolate a single disruptive factor for treatment, since PCOS is often presumed to be the 
result of an endocrine system feedback loop [19]. In addition, the individual presentation of PCOS 
symptoms, resulting in various phenotypes, play a role in the treatment chosen. Because of the 
complex pathophysiology of PCOS, treatment ranges from pharmacological to alternative therapies 
such as acupuncture [20]. Pharmacological options include biguanides to improve insulin sensitivity, 
the oral contraceptive pill to restore menstrual regularity, clomiphene to induce ovulation, and statins 
to lower blood cholesterol [21]. 
Lifestyle modification should be the first line of therapy for women with PCOS [22]. Interventions 
that target insulin sensitivity and, for women with obesity and PCOS, promote weight loss are a 
critical in the management of the condition [23].  Recent research indicates that exercise of a 
moderate intensity (~50-70% VO2max), for approximately 12 weeks, produces improvement in 
cardiometabolic risk factors, including blood pressure, TG, insulin resistance and inflammation, and 
reproductive outcomes such as increased ovulation rates and greater responsiveness to IVF [10,24]. 
The remainder of this chapter will outline and describe current research examining the effects of 
exercise on cardiometabolic, reproductive and mental health outcomes in women with PCOS. 
 
2. Exercise and PCOS  
2.1. Reproductive Function 
PCOS accounts for approximately 80% of women with anovulatory infertility [25]. PCOS causes 
disruption at various stages of the reproductive axis, including the hypothalamus-pituitary axis, 
leading to inappropriate regulation of ovarian steroidogenesis and folliculogenesis [26]. The key 
neuroendocrine abnormalities involved in PCOS are increased gonadotropin-releasing hormone 
(GnRH) pulsatile activity, leading to disproportionate levels of luteinizing hormone (LH) in 
comparison to follicle-stimulating hormone (FSH) [26], known as the LH:FSH ratio. In turn, 
overproduction of LH stimulates ovarian theca cell hyperactivity, culminating in increased ovarian 
steroidogenesis. The lack of FSH stimulation of granulosa cell development and aromatase production 
means that the androgens are not converted to oestrogen, and disruption of follicle maturation and 
ovulation occurs [27,28]. 
2.1.1 Effects of exercise on reproductive function in women with PCOS 
Several studies have explored the impact of exercise interventions on reproductive function, with 
results indicating improvements in menstrual and/or ovulation frequency following exercise  in 
comparison to diet or control groups [29,30,31]. These improvements included a change from non-
ovulatory to ovulatory cycles, restoration of cycle regularity and improvement in inter-cycle variation 
[24] indicating that exercise may be  more beneficial to reproductive function than caloric restriction 
alone. Evidence suggests that the pregnancy rate among women with PCOS undertaking an exercise 
intervention is 35% [31], with pregnancy being a common reason for drop-out amongst participants 
with PCOS in exercise trials [32]. It has been noted that lifestyle modification for overweight or obese 
infertile women with PCOS is a cost-effective solution for those women wishing to conceive, either as 
a primary intervention or in conjunction with fertility treatment [33]. 
It has been suggested that the type and frequency of exercise is not important in improving 
reproductive function in PCOS [24], but contradictory findings suggests otherwise. A recent 
feasibility trial examining the effects of progressive resistance training (PRT) on women with PCOS 
found PRT to be effective at improving cardiometabolic outcomes, but found no such effect on 
reproductive outcomes [34]. The optimal type or intensity of exercise needed in order to elicit a 
response from the reproductive system remains to be elucidated. However, there is an insufficient 
number of studies that examine the impact of resistance training in PCOS [32]. 
Weight loss does not appear necessary to achieve improvements in reproductive function. However, a 
weight loss of as little as 5% may improve spontaneous ovulation rates, reduce associated metabolic 
complications and increase chances of conception [35]. In addition, optimisation of body mass index 
(BMI) into the ‘healthy’ range for women with obesity or overweight may attenuate the risk of 
pregnancy-related complications in women with PCOS, including gestational diabetes, hypertensive 
disorders and premature delivery [36].  
Therefore, for the two-thirds of women with PCOS with overweight or obesity, an exercise 
intervention intended to maximise weight loss may offer additional benefits. This can also be 
important for those overweight women with PCOS, intending to undertake fertility treatment. Excess 
body mass can blunt the response to treatment and higher doses of ovulation-inducing medications 
may be needed [25]. Subsequently, exercise with concurrent weight loss may be optimal and cost-
effective in these cases. If weight loss is to be targeted through exercise interventions, greater weight 
loss is achievable with an intervention of a duration of at least six months [24].  
2.1.2 Mechanism of Action 
In keeping with the presumption of PCOS occurring as a result of an endocrine feedback loop, it is not  
immediately clear whether neuroendocrine abnormalities are a cause or consequence of PCOS [26]. In 
normal menstrual physiology, both estradiol (depending on the stage of folliculogenesis) and 
testosterone provide negative feedback to the hypothalamus to inhibit the frequency and amplitude of 
the GnRH pulse [37]. In PCOS, it appears that persistent elevated androgen levels may decrease the 
sensitivity of the GnRH pulse activator to inhibition by ovarian steroids, preventing the normal 
negative feedback suppression of LH [37,38]. 
The hyperandrogenemic milieu, exacerbated by hyperinsulinemia, may over-stimulate the growth and 
recruitment of antral follicles, which in turn may lead to threefold higher concentrations of anti-
Mullerian hormone (AMH), produced by granulosa cells, in women with PCOS compared to healthy 
women [39]. AMH reduces follicular sensitivity to FSH and serves a purpose to prevent the depletion 
of all primordial follicles at once [40]. However, elevated concentrations may disrupt folliculogenesis 
by inhibiting aromatase and preventing the selection of a dominant follicle, resulting in follicular 
arrest at the small antral stage [39]. 
Enhanced insulin sensitivity underpins the mechanisms of how exercise restores reproductive function 
[24]. Reducing hyperinsulinemia decreases ovarian steroidogenesis and increases SHBG, and the 
resulting return to a normo-androgenic environment may restore sensitivity of the GnRH pulse 
activator to steroid inhibition of LH. Subsequently, decreased levels of LH and androgens may halt 
the excessive recruitment of antral follicles, allowing a dominant follicle to mature, eventually leading 
to ovulation. 
Weight loss in PCOS, either with or without exercise, can lead to reductions in visceral fat as 
indicated by improvements to waist-to-hip (WHR) ratio, a measure which is strongly correlated with 
insulin resistance [24]. Indeed, studies reporting a reduction in WHR have also reported reductions of 
fasting insulin [24]. Subsequently, the resultant reduction in circulating androgens may explain the 
additional benefits of weight loss in overweight or obese women with PCOS. 
3.1 Cardiometabolic Outcomes 
Women with PCOS typically have a cluster of metabolic abnormalities that are risk factors for CVD. 
These include obesity, metabolic syndrome, impaired glucose tolerance, hypertension, impaired 
endothelial and myocardial function, and dyslipidemia [14,41,42]. Evidence suggests that sub-clinical 
atherosclerosis, indicated by carotid intima-media thickness (cIMT), is higher in women with PCOS 
compared to weight-matched controls [41,43]. Additionally, PCOS is associated with increased low-
grade inflammation, with higher circulating concentrations of many inflammation markers that 
mediate CVD, such as C-reactive protein, increased white cell count, neutrophil/lymphocyte ratio, 
tumour-necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) [44,45,46,47,48,49]. It follows that 
women with PCOS have a 50% increased risk of CVD events compared to weight-matched 
counterparts [14] and that the rate of diabetes is 2.6 times higher than that of the general female 
population [50]. 
There has been a lot of discussion on whether the increased association with CVD risk factors is due 
to PCOS itself, or whether it is due to the associated obesity. Indeed, the increased rate of diabetes in 
women with PCOS positively correlated with BMI [50]. However, while obesity may certainly be an 
exacerbating factor [19], it is estimated that at least half of women with PCOS are not overweight or 
obese [50]. As evidenced by those risk factors that are increased in comparison to weight-matched 
healthy women, there are clearly additional mechanisms underlying the increased CVD risk in PCOS. 
Nevertheless, a common feature in both overweight and lean women with PCOS is central adiposity 
[16]; the tendency for fat to accumulate around the abdominal area, including both visceral fat and the 
subcutaneous fat present underneath the skin. A woman with a BMI within the ‘healthy’ range could 
still exhibit abdominal obesity due to excessive visceral fat. This type of body composition may 
contribute to insulin resistance because visceral fat secretes IL-6, an adipokine that inhibits insulin-
mediated glycogenesis and stimulates hepatic (liver) gluconeogenesis [51]. 
3.1.1 Effects of Exercise on Cardiovascular Disease Risk Factors in women with PCOS 
There is irrefutable evidence that exercise mitigates CVD risk factors in healthy populations [52], 
populations with dyslipidemia [53], populations with metabolic syndrome [54,55], and in women with 
PCOS [56]. One of the most prominent studies is the case-control INTERHEART study, which found 
moderate to vigorous intensity exercise to be one of nine lifestyle modifications that are protective 
against myocardial infarction (heart attack) [57]. However, some studies have produced inconsistent 
results with respect to the effectiveness of exercise only, without any additional dietary or 
pharmacological interventions, in improving biomarkers of CVD risk: This is particularly true 
regarding cholesterol and lipoprotein concentrations [10], and inflammation [58]. 
Longer exercise interventions (e.g.  >20 weeks;  [54,55,59]) are associated with improved lipid 
profile, and the reversal of metabolic syndrome in healthy populations. This might account for some 
of the discrepancy in PCOS research, with exercise interventions typically ranging from eight to 24 
weeks in duration. PCOS studies with longer intervention durations have found improvements in 
VLDL and HDL [60], whereas shorter interventions have found no change in LDL and HDL, despite 
improvements in cardiorespiratory fitness [10]. In order to promote changes to blood lipids in a 
shorter duration, the addition of a dietary component may make this achievable [30]. 
Exercise interventions for 12 weeks, 3 sessions per week, can promote weight loss and reductions in 
BMI in women with PCOS [10]. These changes are typically associated with a reduction in WHR or 
waist circumference, indicating a decrease in abdominal obesity. Waist circumference and WHR may 
be a better indicator of health than BMI alone because of its association with other CVD risk factors, 
such as impaired glucose metabolism [57,61]. While changes to BMI and waist circumference seem 
to be more effectively reduced with combined exercise and dietary interventions in comparison to 
dietary intervention alone, weight loss is still achievable in shorter exercise-only interventions [24]. 
However, the amount of weight lost seems to be proportionately related to duration of the intervention 
[10] Longer duration (20 weeks+) may be the key to promote greater weight loss, irrespective of type 
and frequency of exercise [30]. 
In the INTERHEART study, hypertension is well recognised as a CVD risk factor, stated as one of the 
main modifiable risk factors responsible for most incidents of myocardial infarction [57]. 
Hypertension is one of the key characteristics of metabolic syndrome, and there is an inverse 
relationship between blood pressure and insulin sensitivity [54]. Evidence supports the role of 
exercise as treatment for hypertension, with exercise training decreasing blood pressure in around 
75% of hypertensive adults, with a more pronounced affect in women [62].  
In women with PCOS, the results are less clear; some studies find no statistically-significant 
improvements in systolic blood pressure (SBP) or diastolic blood pressure (DBP) in exercise 
interventions from 12 to 24 weeks [63,64], while others have found small, but clinically-meaningful, 
improvements in SBP with exercise or exercise in combination with dietary intervention [30,65]. 
These conflicting results may be due to the wide range of phenotypes possible under the PCOS 
diagnostic criteria; indeed, prevalence of hypertension in PCOS is reported to  be between 5.5-12% 
[66,67] and as such many PCOS participants may be normo-tensive. 
Finally, there is much evidence to support the role of exercise as treatment for one of the most 
common metabolic aberrations of PCOS: insulin resistance. PCOS research supports the role of 
exercise in improving insulin sensitivity immediately after an acute bout of exercise [68], but also in 
the long-term with exercise interventions from three months [65,69] to 20+ weeks [30,31]. Insulin 
resistance has been linked to abdominal obesity, hypertension, the development of type II diabetes 
(T2D) [70], dyslipidemia, and inflammation [71], meaning it is a key indicator of CVD risk in women 
with PCOS, where the prevalence of insulin resistance is up to 80% [11], independent of weight. 
Improvements in insulin sensitivity and/or hyperinsulinemia in PCOS have been associated with 
lowered androgen concentrations [72] and improvements in many of the other CVD risk factors 
mentioned previously [24,73], providing support for the role of insulin resistance as a key, 
underpinning mechanism in the pathophysiology of PCOS. 
3.1.2 Mechanisms of Action 
The mechanism by which exercise improves many CVD risk factors is again associated with 
improved insulin sensitivity and decreased hyperinsulinemia. In PCOS, the cause of insulin resistance 
is hypothesised to be caused by a post-receptor defect in insulin signalling, where phosphorylation of   
insulin-receptor substrate -1 (IRS-1) serine residues is increased while the phosphorylation of the 
tyrosine residues is decreased [72]. This exaggerated serine phosphorylation may cause a decrease in 
insulin-stimulated IRS-1 activation and subsequently a decrease in translocation of glucose transporter 
4 (GLUT4), the insulin sensitive glucose transport protein, leading to decreased cellular glucose 
uptake [74,75]. 
The pro-inflammatory cytokine TNF-a is elevated in PCOS independent of obesity, and TNF-a is a 
known mediator of insulin resistance by inducing the exaggerated serine phosphorylation of IRS-1 
[75]. TNF-a is produced by visceral adipose tissue [76], and this increased distribution of intra-
abdominal fat has been shown to be more prevalent in women with PCOS compared to weight-
matched controls [77]. In addition, intra-abdominal fat releases more free-fatty acids (FFA) into 
circulation than subcutaneous fat [74], and the increased availability of FFA may lead to storage of 
lipids in non-adipose tissue such as muscle cells, leading to lipotoxicity and inflammation [71,72,78]. 
The accumulation of these intra-myocellular lipid metabolites (such as diacylglycerols and ceramides) 
have been postulated to activate intra-cellular serine kinases which may be key to the insulin-
signalling pathway defect that results in insulin resistance [72,78] Women with PCOS have been 
shown to have increased FFA availability [78]. 
Obesity in PCOS also exacerbates insulin resistance and inflammation due to hypoxia-related 
adipocyte death, resulting from adipose tissue expansion. This leads to mononuclear-cell (MNC) 
infiltration which become macrophages, subsequently releasing TNF-a and IL-6, contributing to 
insulin resistance [71,75]. However, even in the absence of obesity, MNC sensitivity to glucose is 
increased in PCOS, and glucose ingestion promotes an inflammatory response [75]. 
Exercise improves glucose and insulin metabolisms by restoring glucose homeostasis through 
increased skeletal muscle glucose disposal [79]. This is achieved via increases in: i) skeletal muscle 
capillarisation, ii) expression of glucose transporter proteins, and iii) mitochondrial function [80]. 
Indeed, exercise-mediated glucose disposal does not rely on insulin receptor or IRS-1 phosphorylation 
as in normal insulin signalling, but does so through distinct proximal signalling mechanisms [79]. 
Chronic exercise increases mitochondrial content and activity, and this is associated with improved 
skeletal muscle insulin sensitivity and whole body metabolic health [80]. A possible mechanism for 
this is the increased mitochondrial lipid oxidation of intra-myocellular lipid metabolites, which 
interfere with insulin signalling [78]. The subsequent improvement in insulin sensitivity may therefore 
reduce inflammation and the release of cytokines that promote insulin resistance. In addition, as 
previously outlined, weight loss (in particular a reduction in abdominal obesity) is often associated 
with exercise in PCOS [24], and this reduction of the metabolically active visceral adipocytes may 
also lead to reduced secretions of TNF-a and IL-6. 
The resulting improvement in insulin metabolism may lead to improved lipid profile through 
decreased mobilisation of FFA through lipolysis, and the increased uptake and storage of glucose and 
triglycerides [71]. Blood pressure may also be reduced by improving insulin sensitivity. In the insulin-
resistant state, compensatory hyperinsulinemia results in vasoconstriction and increased sodium 
reabsorption which lead to hypertension [54,71]. Thus, exercise bestows a multitude of positive 
effects that reduce many of the CVD risk factors associated with PCOS. 
 
4.1 Mental Health and Psychological Wellbeing 
In addition to a multitude of cardiometabolic and reproductive complications, PCOS has been 
associated with an increased prevalence of mental health disorders [81,82,83,84,85,86] . PCOS 
symptomology includes a number of features that are associated with poor body image and decreased 
quality of life, such as obesity, acne, excess body hair growth,  scalp hair thinning, infertility and 
menstrual irregularity [82].  
Research has long identified a link between women with PCOS and increased incidences of 
depression and anxiety [81]; a recent report suggests that the odds ratio (OR) for women with PCOS 
compared to controls for depression and anxiety is 1.26 and 2.76, respectively [82]. In China, a study 
of 120 patients with PCOS and 100 controls reported the prevalence of anxiety and depression to be 
13.3% and 27.5% in PCOS compared to 2% and 3% in controls [83]. Similarly, a study in India of 
110 PCOS patients and 40 controls identified the prevalence of major depressive disorder and 
generalised anxiety disorder (GAD) to be 23.64% and 15.45% in PCOS, compared to 7.5% and 0% in 
controls [85]. The increased prevalence of mental health disorders is not limited to depression and 
anxiety. Reports also indicate an increased prevalence of bipolar disorder [87], personality disorders 
[86] and binge eating disorders [88]. 
 
4.1.1 Effects of Exercise on Mental Health in women with PCOS 
 
The benefits of exercise on psychological well-being, including improvements in mood, reduced 
depressive symptoms, and improved body-image and quality of life are documented in overweight 
women [89,90] and adults in general [91,92]. However, this is less well-documented in women with 
PCOS. While various studies have assessed the impact of an exercise intervention on health-related 
quality of life (HRQoL) in PCOS, these have mostly been combined ‘lifestyle’ interventions with 
exercise undertaken as an adjunct to different diets [93,94] or drug therapy [95].  
Other studies have compared exercise alone with other treatment groups, rather than a standard-care 
or control group [96]. These include the comparison of exercise with both an acupuncture group and a 
control group [97], and the comparison of a traditional exercise programme with yoga among 
adolescents [98]. Despite not being able to isolate the effects of exercise independently, most 
interventions including exercise improved HRQoL, anxiety or self-esteem [93,94,97,98], suggesting 
that exercise has a place in a lifestyle intervention aimed at improving mental wellbeing in women 
with PCOS [96]. 
Moreover, cross-sectional and observational studies lend support to the idea that physically active 
women with PCOS are likely to have less severe depression, or no depression, compared to inactive 
women with PCOS [99,100]. The psychological benefits of exercise are not necessarily related to 
weight loss since an observational study of women with PCOS found that those completing a self-
directed brisk walking programme improved their body image significantly in comparison to those 
women who did not complete the walking intervention, despite no changes to BMI [101].  
4.1.2 Mechanisms of Action 
 
The mechanisms by which exercise improves psychological well-being in women with PCOS is 
dependent on certain physiological factors. For example, various studies suggest increased mental 
distress related to body image in women with overweight or obesity  [84,101]. Exercise interventions 
(combined with diet) that result in weight-loss lead to improved self-esteem and HRQoL [93,94]. As 
outlined previously in the chapter, exercise and associated weight-loss may also improve fertility 
which is another factor that improves HRQoL. Improvements in BMI may also reduce sleep 
disturbances which affect day-to-day functioning [84]. For example, obstructive sleep apnea (OSA) is 
closely related to obesity and insulin resistance, and weight loss is a key treatment of this condition, 
which may increase sleep duration [102]. Indeed, research reports that women with PCOS may be 30 
times more likely to experience sleep disordered breathing than controls [103]. 
Another physiological factor may be the cycle of inflammation and impaired insulin metabolism 
present in PCOS that has been described previously. Clinical and experimental evidence links 
activation of the brain cytokine system to depression [104] and may be a factor in the increased 
prevalence of depression in PCOS. Subsequently, interventions that reduce obesity-related 
inflammation or normalise insulin metabolism to the effect of reducing pro-inflammatory cytokines, 
may reduce rates of depression. In addition, severity of hyperandrogenism experienced by the 
individual may be related to higher levels of mental stress in PCOS because of the clinical 
presentation. That is, cystic acne, hirsutism and thinning scalp hair which may lead to negative self-
image and poor self-esteem [81,84]. Exercise can restore insulin sensitivity and thus reduce 
hyperinsulinemia [24], which causes ovarian steroidogenesis and reduces hepatic output of SHBG, 
leading to hyperandrogenemia. The subsequent reduction in androgens may therefore improve the 
related clinical symptoms and improve body-image.  
Finally, research indicates that women with PCOS may have enhanced hypothalamus-pituitary-
adrenal (HPA) axis activity in response to stress, characterised by markedly increased psychological 
distress, which may provide a link between PCOS and the increased prevalence of mental health 
disorders [105]. Habitual physical activity may modulate the sympathetic nervous system’s response 
to stress and therefore reduce the negative impact of stress on health [106,107]. 
5. Translating Evidence into Practice: Exercise Programming 
 
The summary of current research outlined in this chapter provides compelling evidence that exercise 
can be used to alleviate or mitigate many of the cardiovascular, metabolic, reproductive and 
psychological aberrations that are associated with PCOS. While a single, unifying theory of the cause 
of this disorder is yet to be found, the main theories for the aetiology of PCOS include primary 
disordered gonadotropin secretion, primary ovarian and adrenal hyperandrogenism, and primary 
insulin resistance [28]. Whichever the true cause may be, exercise has been shown to play a role in 
normalising symptoms associated with each suggested aetiology. 
An optimal dose-response relationship to exercise in PCOS may not be feasible because of the highly 
individualised characteristics of the disorder. Indeed, the AE-PCOS Society suggests that 
individualised exercise programmes may improve compliance, and suggest group or home exercise 
[108].  
Specifically, Australian guidelines for PCOS suggest at least 150 minutes of physical activity per 
week [109]. This is in line with current UK physical activity guidelines for adults aged 19-64 years, 
and this should form the basis of any clinician or healthcare professional prescription. Most research 
examining the effects of exercise on PCOS symptoms is aerobic such as walking, jogging, running 
and / or cycling [24,56,110]. For example, many of the benefits associated with exercise can be 
obtained by brisk walking, defined as faster than normal walking but at a pace that could be sustained 
for at least 20 minutes, and this is also the mode suggested by the AE-PCOS Society [101,108].  
Metabolic improvements are possible in as little as 12-weeks [10]. However, if weight-loss and/or 
improvement to lipid profile is also recommended, women with PCOS should undertake exercise 
programmes of longer duration (20+ weeks), and/or consider the inclusion of a dietary component to 
achieve the best results, regardless of type or frequency of the exercise [30,54,55,64]. 
Higher-intensity exercise (90-100% VO2max) is less well-documented. However, positive 
improvements to insulin metabolism have been shown with high-intensity interval training sessions in 
PCOS [10,111]. In addition, PRT is a mode of exercise that complementary to its effectiveness in 
treating insulin resistance, may also decrease the loss of fat-free mass (FFM) and increase lean body 
mass, whilst simultaneously reducing waist circumference [34,112]. This may be a particularly 
important consideration for older women at risk of sarcopenia [113]. 
Regardless, an effective exercise programme that is engaging and that women with PCOS will adhere 
to is one that is client-centred, offering a choice of modes that may suit a variety of women of 
different physical abilities and preferences. In addition, the presence and support of other people may 
be a contributing factor to the compliance of an exercise programme, and group or supervised 
exercise sessions should be considered in addition to solitary exercise [96]. 
6. Practical Considerations for Exercise Prescription in PCOS 
It is important to consider the practical applications of exercise prescription for women with PCOS. 
Below are some key points to keep in mind to maximise adherence to an exercise intervention: 
1. Consider that the client may have issues or anxieties surrounding body-image and self-
esteem. As such, individual exercise sessions or small groups within private facilities may be 
more effective than large, publicly accessible gym spaces. 
2. Clients should be informed of the benefits of exercise and physical activity even in the 
absence of weight loss, such as improved cardiovascular and metabolic health and increases 
in mental health and wellbeing.  
3. Enjoyment should be a key tenet of an exercise intervention; try to ask the client about 
previous exercise modes they have enjoyed and implement these.  
4. Undertake individual fitness testing and assessment before commencement of the programme 
and use the results to set bespoke training thresholds for the client. This will avoid discomfort 
from over-exertion which may increase injury risk and impact adherence. 
5. In addition, if the client is not or has not been a habitual exerciser, begin training at low 
aerobic thresholds, i.e. 55-60%HRmax and increase the thresholds as the individual adapts to 
the demands of exercise. 
6. For very untrained individuals, intermittent activity with regular breaks may be more 
achievable at first. 
7. If increased risk for CVD is present, such as hypertension and T2D, close monitoring of heart 
rate and rate of perceived exertion (RPE) is recommended. 
 
7. Key Points 
- PCOS is a complex endocrinopathy affecting up to 20% of reproductive-aged women. It is 
associated with cardiometabolic and reproductive complications. Symptoms may be 
exacerbated by obesity.  
-  Insulin resistance is a key underpinning feature and exercise programmes that attenuate 
insulin resistance or hyperinsulinemia may be integral to improving associated symptoms. 
- Research shows that exercise can improve reproductive function, cardiovascular and 
metabolic health, and mental well-being. 
Weight loss is not necessary for health improvements, and clinicians and healthcare 
professional should use the minimum physical activity guidelines as a basis to prescribe 
exercise. 
- Future research may be beneficial in indicating the efficacy of different exercise intensities, 
such as high-intensity exercise and progressive resistance training. 
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